Nat Commun:药物“利他林”的副作用

2013-11-14 Nature中文网 Nature中文网

药物“利他林”(利他能)中的活性成分Methylphenidate能增强大脑对进一步接触该药物的反应方式,同时在自行食用时还能增强大鼠寻找“安非他明”的行为。在本期Nature Communications上报告的这些发现揭示了也用于娱乐消遣目的的一种处方药隐藏的副作用。【原文下载】 在西方国家,Methylphenidate被普遍作为处方药用于治疗多动症(ADHD)和嗜睡症,但因其所报道的认知

药物“利他林”(利他能)中的活性成分Methylphenidate能增强大脑对进一步接触该药物的反应方式,同时在自行食用时还能增强大鼠寻找“安非他明”的行为。在本期Nature Communications上报告的这些发现揭示了也用于娱乐消遣目的的一种处方药隐藏的副作用。【原文下载

在西方国家,Methylphenidate被普遍作为处方药用于治疗多动症(ADHD)和嗜睡症,但因其所报道的认知增强效应和愉悦效应也被用于消遣。然而,关于消遣性使用Methylphenidate所产生的神经生物影响的现有信息却是有限的。为了解决这一问题,Sara Jones及同事允许大鼠自行食用Methylphenidate,发现这会引起多巴胺转运蛋白(与上瘾行为有很大关系)水平的增加。他们进而发现,由Methylphenidate诱导的多巴胺转运蛋白水平的增加与寻找Methylphenidate以及性质相似的其他药物如“安非他明”的行为的增加直接相关。

作者提出,人类中多巴胺转运蛋白水平的个体差异(这些差异已在ADHD患者和“创伤后应激障碍”患者中观察到)也许能预测对Methylphenidate和“安非他明”等药物的滥用的易感性。然而,还需要对人类做进一步的研究来确认这一点。

原文出处

Calipari ES, Ferris MJ, Salahpour A, Caron MG, Jones SR.Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression.Nat Commun. 2013 Nov 5;【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086667, encodeId=700c208666e1d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jun 12 18:19:00 CST 2014, time=2014-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824179, encodeId=99bc18241e9ba, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Aug 03 20:19:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879754, encodeId=2f2a18e97541d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 12 04:19:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]
    2014-06-12 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086667, encodeId=700c208666e1d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jun 12 18:19:00 CST 2014, time=2014-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824179, encodeId=99bc18241e9ba, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Aug 03 20:19:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879754, encodeId=2f2a18e97541d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 12 04:19:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086667, encodeId=700c208666e1d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jun 12 18:19:00 CST 2014, time=2014-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824179, encodeId=99bc18241e9ba, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Aug 03 20:19:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879754, encodeId=2f2a18e97541d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Apr 12 04:19:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]
    2014-04-12 liye789132251

相关资讯

JAMA PSYCHIAT:利他林或可用于成瘾性疾病治疗

这一研究发表于近期《美国医学会杂志-精神病学》(JAMA Psychiatry.Published online June 26, 2013)。研究发现,盐酸哌甲酯(Methylphenidate,商品名:利他林)可调节大脑中某些特定通路的连接,而这些通路被认为与可卡因成瘾患者的自我控制及对药物的渴求有关。既往研究显示,口服盐酸哌甲酯可以改善可卡因成瘾患者的脑功能,这表现在某些特别的认知功能中,如